Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
Epe47MyxVJt3EbCP
Listen
